Market capitalization | $51.33m |
Enterprise Value | $44.10m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 55.13 |
P/S ratio (TTM) P/S ratio | 64.16 |
P/B ratio (TTM) P/B ratio | negative |
Sales growth (TTM) Sales growth | 133.06% |
Turnover (TTM) Turnover | $800.00k |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
4 Analysts have issued a VolitionRX forecast:
4 Analysts have issued a VolitionRX forecast:
Dec '23 |
+/-
%
|
||
Turnover | 0.78 0.78 |
152%
152%
|
|
Gross income | -0.64 -0.64 |
27%
27%
|
|
EBITDA | -35 -35 |
13%
13%
|
EBIT (operating result) EBIT | -36 -36 |
13%
13%
|
Net profit | -35 -35 |
17%
17%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
Head office | United States |
CEO | Cameron Reynolds |
Employees | 110 |
Founded | 1998 |
Website | www.volition.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.